[Skip to Content]
[Skip to Content Landing]
August 14, 1972


JAMA. 1972;221(7):715. doi:10.1001/jama.1972.03200200061028

To the Editor.—  In a study carried out among Swedish tourists from 1963 to 1966 it was found that the Entero-Vioform oxyquinoline was not only ineffective in preventing Salmonella infections, but did, in fact, increase the risk of contracting such infections.1 In another investigation carried out in vitro it was found that the minimum inhibitory concentration of iodochloroxyquinoline and dibromoxyquinoline was higher for salmonella strains than for most other aerobic bacteria usually found in the intestine. In mice given a prophylactic treatment with oxyquinolines, and later a challenge dose of Salmonella, the death rate was approximately twice as high as in untreated controls.2These findings, in addition to the reports concerning subacute myelooptic neuropathy (SMON) have caused the health authorities in Sweden to reduce the use of oxyquinoline derivatives in Sweden. From June 1, 1972, such preparations are available with prescription only and recommended only for treatment of